Evidence of impaired cisapride metabolism in neonates
نویسندگان
چکیده
منابع مشابه
Effects of cisapride on QTc interval in neonates.
AIM Prospective survey of the effects of cisapride on QTc interval in neonates given cisapride. METHODS QTc interval was determined just before and 2.9 (0.9) days after outset of the treatment in 49 neonates treated with cisapride between 1 August 1995 and 29 February 1996. RESULTS Cisapride significantly increased QTc interval (p = 0.0001), and this was higher when birthweight or gestation...
متن کاملEffects of cisapride on QTc interval in term neonates.
BACKGROUND Cisapride administration for 48 hours has been shown to increase heart rate corrected QT (QTc) interval in preterm neonates. Accumulation of the drug because of liver enzyme immaturity has been suggested to be the reason. If this is correct, a longer survey of QTc interval should disclose an increase even in term neonates. OBJECTIVE A prospective survey of the effects of cisapride ...
متن کاملevidence of adverse selection in irans health insurance market
در این تحقیق به مطالعه وجود انتخاب نامساعد(کژ گزینی) در بازار بیمه درمان تکمیلی ایران پرداخته شده است. داده های مورد نیاز توسط پرسشنامه و به روش نمونه گیری خوشه ای جمع آوری شده است. پرسشنامه ها در میان افراد شاغل ساکن شهر تهران توریع شد. در این تحقیق با استفاده از تخمین دو مدل لجستیک و به دست آوردن ضریب همبستگی میان تقاضای بیمه درمان تکمیلی و رخداد خسارت به بررسی موضوع مورد نظر پرداخته شده است....
15 صفحه اولAnnotations The risks and benefits of cisapride in premature neonates, infants, and children
The Medicines Control Agency and the Committee on Safety of Medicines (CSM) recently stated that cisapride is contraindicated in infants born before 36 weeks’ gestation for three months after birth, and that there is insuYcient data to support the use of cisapride in children up to 12 years of age. These statements need qualification. Many believe cisapride to be a safe and useful agent in a va...
متن کاملThe risks and benefits of cisapride in premature neonates, infants, and children.
The Medicines Control Agency and the Committee on Safety of Medicines (CSM) recently stated that cisapride is contraindicated in infants born before 36 weeks’ gestation for three months after birth, and that there is insuYcient data to support the use of cisapride in children up to 12 years of age. These statements need qualification. Many believe cisapride to be a safe and useful agent in a va...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Clinical Pharmacology
سال: 2001
ISSN: 0306-5251
DOI: 10.1046/j.0306-5251.2001.01470.x